oki-179
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 8, 2019 (NCT03931681)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05340621 | Phase 1/Phase 2 (Phase 2) | May 11, 2022 | Harvard University, OnKure, Inc. |
| NCT03931681 | Phase 1 | May 8, 2019 | OnKure, Inc., University of Colorado, Denver |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OnKure, Inc. | For profit | 2 | 2 | 2 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1